Autoimmunity and Bone
暂无分享,去创建一个
E. Schwarz | R. O’Keefe | L. Xing | B. Boyce | C. Ritchlin | R. Looney | M. Drissi | R. Looney | R. JOHN LOONEY | M. HICHAM DRISSI
[1] V. Pascual,et al. Autoimmunity through cytokine-induced dendritic cell activation. , 2004, Immunity.
[2] E. Schwarz,et al. RANK Signaling Is Not Required for TNFα‐Mediated Increase in CD11bhi Osteoclast Precursors but Is Essential for Mature Osteoclast Formation in TNFα‐Mediated Inflammatory Arthritis , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[3] V. Pascual,et al. The central role of dendritic cells and interferon-&agr; in SLE , 2003 .
[4] David L. Lacey,et al. Osteoclast differentiation and activation , 2003, Nature.
[5] Virginia Pascual,et al. Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus Blood , 2003, The Journal of experimental medicine.
[6] D. Choubey,et al. Type-I Interferon Receptor Deficiency Reduces Lupus-like Disease in NZB Mice , 2003, The Journal of experimental medicine.
[7] E. Schwarz,et al. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. , 2003, The Journal of clinical investigation.
[8] G. Karypis,et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[9] Alexander Fraser,et al. Angiopoietins, growth factors, and vascular morphology in early arthritis. , 2003, The Journal of rheumatology.
[10] J. Meyers,et al. Immune-mediated inflammatory disorders (I.M.I.D.s): the economic and clinical costs. , 2002, The American journal of managed care.
[11] E. Schwarz,et al. Exposure to receptor-activator of NFκB ligand renders pre-osteoclasts resistant to IFN-γ by inducing terminal differentiation , 2002, Arthritis research & therapy.
[12] C. Edwards. Immune-mediated inflammatory disorders , 2002 .
[13] D. Aaronson,et al. A Road Map for Those Who Don't Know JAK-STAT , 2002, Science.
[14] D. Goeddel,et al. TNF-R1 Signaling: A Beautiful Pathway , 2002, Science.
[15] Kozo Nakamura,et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β , 2002, Nature.
[16] P. Mease,et al. Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors , 2002, Annals of the rheumatic diseases.
[17] W. Arend,et al. The innate immune system in rheumatoid arthritis. , 2001, Arthritis and rheumatism.
[18] R. Locksley,et al. The TNF and TNF Receptor Superfamilies Integrating Mammalian Biology , 2001, Cell.
[19] T. Vyse,et al. Enhanced Susceptibility to Lupus Contributed from the Nonautoimmune C57BL/10, But Not C57BL/6, Genome1 , 2000, The Journal of Immunology.
[20] C. Drake,et al. Contributions of Ea(z) and Eb(z) MHC genes to lupus susceptibility in New Zealand mice. , 1998, Journal of immunology.
[21] C. Drake,et al. Control of multiple autoantibodies linked with a lupus nephritis susceptibility locus in New Zealand black mice. , 1997, Journal of immunology.
[22] C. Drake,et al. Effect of genetic background on the contribution of New Zealand black loci to autoimmune lupus nephritis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[23] V T Farewell,et al. Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model. , 1995, The Journal of rheumatology.
[24] C. Drake,et al. Analysis of the New Zealand Black contribution to lupus-like renal disease. Multiple genes that operate in a threshold manner. , 1995, Journal of immunology.
[25] L. Espinoza,et al. Coexistence of human immunodeficiency virus infection and systemic lupus erythematosus. , 1995, The Journal of rheumatology.
[26] S. Sarna,et al. Correlations between clinical facets of outcome in rheumatoid arthritis. , 1993, Clinical and experimental rheumatology.
[27] R. Luukkainen,et al. How often is seropositive rheumatoid arthritis an erosive disease? A 17-year followup study. , 1993, The Journal of rheumatology.
[28] D. Kioussis,et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. , 1991, The EMBO journal.
[29] E. Atra,et al. A study of synovial membrane of patients with systemic lupus erythematosus (SLE). , 1991, Clinical and experimental rheumatology.
[30] D. Resnick. Bone and Joint Imaging , 1989 .
[31] D. Woolley,et al. Bidirectional erosion of cartilage in the rheumatoid knee joint. , 1985, Annals of the rheumatic diseases.
[32] J. Esdaile,et al. Deforming arthritis in systemic lupus erythematosus. , 1981, Annals of the rheumatic diseases.
[33] D. Goldenberg,et al. SYNOVIAL MEMBRANE HISTOPATHOLOGY IN THE DIFFERENTIAL DIAGNOSIS OF RHEUMATOID ARTHRITIS, GOUT, PSEUDOGOUT, SYSTEMIC LUPUS ERYTHEMATOSUS, INFECTIOUS ARTHRITIS AND DEGENERATIVE JOINT DISEASE , 1978, Medicine.
[34] J. Edmonds,et al. Systemic lupus erythematosus. A prospective analysis. , 1978, Annals of the rheumatic diseases.
[35] H. Schumacher,et al. Articular manifestations of systemic lupus erythematosus. , 1971, Annals of internal medicine.
[36] Kaposi. Neue Beiträge zurKenntniss des Lupus erythematosus , 1872, Archiv für Dermatologie und Syphilis.
[37] L. Pasquier,et al. Orphanet Journal of Rare Diseases BioMed Central Review , 2006 .
[38] E. Schwarz,et al. Systemic tumor necrosis factor α mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor α–transgenic mice , 2004 .
[39] E. Schwarz,et al. Systemic tumor necrosis factor alpha mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor alpha-transgenic mice. , 2004, Arthritis and rheumatism.
[40] J. Bonnefoy,et al. Interferon-γ switches monocyte differentiation from dendritic cells to macrophages , 2003 .
[41] V. Pascual,et al. The central role of dendritic cells and interferon-alpha in SLE. , 2003, Current opinion in rheumatology.
[42] J. Bonnefoy,et al. Interferon-gamma switches monocyte differentiation from dendritic cells to macrophages. , 2003, Blood.
[43] M. Feldmann,et al. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. , 2003, Nature medicine.
[44] P. Schur. The clinical management of systemic lupus erythematosus , 1996 .
[45] W. Eyler,et al. PSORIATIC ARTHRITIS. , 1965, Henry Ford Hospital medical bulletin.